Tagraxofusp

證據等級: L5

預測適應症: 10 個

Tagraxofusp: From CD123+ Hematologic Malignancy to Pre-malignant Myeloid Neoplasm (MDS/CMML)

One-Sentence Summary

Tagraxofusp is a CD123 (IL-3 receptor α)-targeted diphtheria toxin fusion protein used to eliminate CD123-expressing malignant cells, most notably in blastic plasmacytoid dendritic cell neoplasm (BPDCN) and AML blasts. Among the TxGNN candidates reviewed, the only prediction with actual clinical evidence is pre-malignant neoplasm (MDS/CMML), supported by 5 clinical trials but no dedicated publications. The nine other top-ranked TxGNN predictions (esotropia, inner ear neoplasm, benign tongue neoplasm, etc.) have no clinical trials and no relevant literature, and are assessed as graph noise with no mechanistic plausibility — they are not carried forward in this report.

Quick Overview

Item	Content
Original Indication	Not documented in Taiwan regulatory data (drug not marketed in Taiwan); evidence-pack rationale text indicates approved use in CD123+ hematologic malignancies (BPDCN, AML)
Predicted New Indication	Pre-malignant neoplasm (MDS / CMML — CD123+ clonal disorders)
TxGNN Prediction Score	99.73% (rank 2 of 10)
Evidence Level	L2
Taiwan Market Status	✗ Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action documentation for tagraxofusp is not yet available in our source database (flagged as a High-severity data gap). Based on information embedded in the evidence pack’s own rationale text, tagraxofusp is a CD123 (IL-3Rα)-targeted diphtheria toxin fusion protein, designed to selectively kill CD123-expressing malignant cells such as BPDCN blasts and AML blasts.

Myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) are widely regarded as pre-malignant/clonal myeloid disorders, and their blast populations frequently co-express CD123 — the same target exploited by tagraxofusp in its approved indications. This provides a mechanistically coherent rationale for extending tagraxofusp into earlier, pre-leukemic clonal disease, consistent with its established activity against CD123+ AML blasts.

By contrast, the model’s top-ranked prediction (esotropia) and several other high-scoring candidates (inner ear neoplasm, benign tongue neoplasm, bronchial carcinoid, chondroid hamartoma, non-seminomatous lesion, cystic neoplasm, thyroglossal duct cyst) have no known CD123 biology and no supporting evidence — these should be treated as knowledge-graph artifacts rather than genuine repurposing signals.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06414681	Early Phase 1	Not Yet Recruiting	20	Tagraxofusp + pacritinib in intermediate-1+ myelofibrosis patients who failed/are unsuitable for JAK inhibitors; directly relevant to pre-malignant myeloid disease but not yet enrolling
NCT05476770	Phase 1	Recruiting	54	Tagraxofusp ± chemotherapy in pediatric relapsed/refractory CD123+ hematologic malignancies; mechanism-relevant but population is confirmed malignancy, not strictly pre-malignant
NCT03113643	Phase 1	Recruiting	72	SL-401 (tagraxofusp) + azacitidine in high-risk MDS, and + azacitidine/venetoclax in AML/BPDCN; MDS arm most directly supports the “pre-malignant” hypothesis
NCT07148180	Phase 1/2	Recruiting	31	Tagraxofusp + azacitidine + venetoclax targeting measurable residual disease in AML; conceptually adjacent to early/subclinical disease but not a classic pre-malignant population
NCT03386513	Phase 1/2	Active, Not Recruiting	179	Studies IMGN632 (a different CD123-targeted ADC), not tagraxofusp itself — mechanism-analogous evidence only

Literature Evidence

Currently no related literature available specifically addressing tagraxofusp in pre-malignant/MDS-CMML populations.

(Note: 20 publications were retrieved under a separate TxGNN candidate, “ductular or ductular proliferation,” but on review these concern hepatic ductular reaction/liver fibrosis biology and are unrelated to CD123/tagraxofusp mechanism — matched on the word “ductular” only. They are not included here.)

US Market Information

Tagraxofusp is not currently marketed in Taiwan — no license records are available for this drug in the regulatory database.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy — CD123-targeted diphtheria toxin fusion protein (immunotoxin), distinct from conventional cytotoxic chemotherapy
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	As a protein-toxin conjugate targeting malignant/pre-malignant hematologic cells, handling should follow institutional hazardous-drug protocols pending confirmation via official labeling

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug-interaction data for tagraxofusp were not available in the source database at the time of this report (flagged as a Blocking data gap — DG001).

Conclusion and Next Steps

Decision: Hold

Rationale: The only mechanistically plausible and evidence-supported prediction (pre-malignant neoplasm / MDS-CMML) is backed by just one not-yet-recruiting Early Phase 1 trial and two Phase 1 trials with indirect relevance (L2 evidence overall) — not sufficient to advance past a research-question stage. Critical safety data (TFDA/package-insert warnings and contraindications) is missing entirely, which blocks any S1 safety pre-assessment. The nine other top TxGNN-ranked indications lack any clinical or literature support and are assessed as graph noise.

To proceed, the following is needed:

Package insert / official labeling data for warnings, contraindications, and drug interactions (DG001, Blocking)
Confirmed mechanism-of-action and original-indication documentation from DrugBank or regulatory sources (DG002, High)
Monitor enrollment status of NCT06414681 and maturation of NCT03113643 (MDS arm) for direct efficacy signal in pre-malignant disease
Re-evaluate once literature specifically addressing tagraxofusp in MDS/CMML populations becomes available
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.